Biomarin Pharmaceutical Inc. - Registered Shares

-1.14 (-1.09%)
Products, Regulatory

Biomarin Announces Incremental Progress On Biologics License Application (BLA) Review For Valoctocogene Roxaparvovec AAV Gene Therapy For Adults With Severe Hemophilia A Program

Published: 11/07/2022 22:17 GMT
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) - Biomarin Announces Incremental Progress on Biologics License Application (bla) Review for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults With Severe Hemophilia a Program.
Biomarin Pharmaceutical Inc- FDA Pre-licensure Inspection of Gene Therapy Manufacturing Facility Scheduled.
Biomarin Pharmaceutical Inc- FDA Requests Submission of Upcoming 3-year Data Analysis From Phase 3 Gener8-1 Study.
Biomarin Pharmaceutical Inc- Current PDUFA Target Action Date of March 31, 2023, Could Be Extended by 3 Months, If 3-year Data Submission Deemed a Major Amendment.